Thomas G. Martin, III, MD

Approaching MRD in Multiple Myeloma

Thomas G. Martin III, MD;

08/29/2020

Future Therapies in Multiple Myeloma

Thomas G. Martin III, MD;

08/29/2020

Approaching MRD in Multiple Myeloma

Thomas G. Martin III, MD;

03/09/2020

Future Therapies in Multiple Myeloma

Thomas G. Martin III, MD;

03/09/2020

Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis

Introduction:Achievement of minimal residual disease negativity (MRD‚Äì) status in multiple myeloma (MM) is associated with improved progression-free survival (PFS) and overall survival. ...

Nelson Castro ;

Tomas Pika ;

Javier De la Rubia ;

Angelo Maiolino ;

Anthony Reiman ;

Thomas G. Martin III, MD;

Sylvia Marion ;

Joseph Mikhael , MD, MEd, FRCPC;

Roman Hajek ;

Sosana Delimpasi ;

Joaquin Martinez-Lopez ;

Sandrine Mace ;

Phillippe Moreau ;

Kwee Yong ;

Meletios-Athanasios Dimopoulos ;

France Casca ;

Marie-Laure Risse ;

Bradle Augustson ;

11/04/2022

Updated Progression-free Survival (PFS) and Depth of Response in IKEMA, A Randomized Phase 3 Trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) vs Kd in Relapsed Multiple Myeloma (MM)

Introduction:The anti-CD38 antibody Isa in combination with Kd is approved in various countries for patients (pts) with relapsed MM after ‚â•1 prior therapy, based on primary interim anal...

Thomas G. Martin III, MD;

Joseph Mikhael , MD, MEd, FRCPC;

Roman Hajek ;

Sandrine Mace ;

Phillippe Moreau ;

Kwee Yong ;

Marcelo Capra ;

Thierry Facon ;

France Casca ;

Marie-Laure Risse ;

Meletios-Athanasios Dimopoulos ;

11/04/2022